Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA) HIV Vaccine in HIV Uninfected Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy adult males and females, as assessed by a medical history, physical exam, and laboratory tests;~* Age of at least 18 years of age on the day of screening and no greater than 40 years on the day of first vaccination;~* Willing to comply with the requirements of the protocol and available for follow-up for the planned duration of the study (screening plus 18 months);~* In the opinion of the principal investigator or designee has understood the information provided. Written informed consent needs to be given before any study-related procedures are performed;~* Willing to undergo HIV Testing and counseling, and receive HIV test results;~* If sexually active female, using an effective method of contraception from screening until at least 4 months after last vaccination. All female volunteers must be willing to undergo urine pregnancy tests.~* If sexually active male, willing to use an effective method of contraception from screening until 4 months after the last vaccination and will be advised not to get his partner pregnant.~Exclusion Criteria:~* Confirmed HIV-1 or HIV-2 infection;~* Reported high-risk behavior for HIV infection defined as:~Within 6 months before vaccination, the volunteer has:~* Had unprotected vaginal or anal sex with a known HIV infected person or with a casual partner.~* Engaged in sex work for money or drugs~* Used injection drugs (illicit), or~* Acquired an STD;~* Any clinically significant abnormality on history or examination including history of immunodeficiency or autoimmune disease; use of systemic corticosteroids, immunosuppressive, antiviral, anticancer, or other medications considered significant by the trial physician within the last 6 months;~* Any clinically significant acute or chronic medical condition requiring care of a physician (e.g., diabetes, coronary artery disease, rheumatologic illness, malignancy, substance abuse) that in the opinion of the investigator would preclude participation;~* Any of the following abnormal laboratory parameters listed below:~* Hemoglobin: \<9.0 g/dL~* Absolute Neutrophil Count (ANL): ≤ 999/mm3~* Absolute Lymphocyte Count (ALC): ≤ 500/mm3~* Platelets: ≤ 90,000 ≥ 550,000/mm3~* Creatinine: \> 1.4 x ULN~* AST: \>3.0 x ULN~* ALT: \>3.0 x ULN~* Urine dipstick: blood = 2+ or more (except in menstruating females); protein = 2+or more~* Cardiac troponin I: \> ULN;~* Confirmed diagnosis of hepatitis B (surface antigen, HbsAg); hepatitis C (HCV antibodies) or active syphilis;~* If female, pregnant or planning a pregnancy within 4 months after last vaccination or lactating;~* Receipt of a live attenuated vaccine (other than influenza) within 30 days or other vaccine within 14 days of vaccination;~* Receipt of blood transfusion or blood products 6 months prior to vaccination;~* Participation in another clinical study of an investigational product currently or within past 12 weeks or expected participation during this study;~* Receipt of another experimental HIV vaccine at any time;~* History of severe local or systemic reactogenicity to vaccination or history of severe allergic reactions;~* Major psychiatric illness including any history of schizophrenia or severe psychosis, bipolar disorder requiring therapy, suicidal attempt or ideation in the previous 3 years;~* In the opinion of the investigator, unlikely to comply with protocol;~* ECG with clinically significant findings or features that would interfere with the assessment of myo/pericarditis including:~* conduction disturbance (atrioventricular or intraventricular condition, left or right bundle branch block, AV block of any degree, or QTc prolongation)~* repolarization (ST segment or T wave) abnormality~* significant atrial or ventricular arrhythmia~* frequent atrial or ventricular ectopy (e.g. frequent premature atrial contractions, 2 premature ventricular contractions in a row)~* ST elevation consistent with ischemia~* evidence of past or evolving myocardial infarction;~History of, or known active cardiac disease including:~* previous myocardial infarction (heart attack)~* angina pectoris~* congestive heart failure~* valvular heart disease including mitral valve prolapse~* cardiomyopathy~* pericarditis~* stroke or transient ischemic attack~* chest pain or shortness of breath with activity (such as walking up stairs)~* other heart conditions under the care of a doctor;~Have 3 or more of the following risk factors:~* high blood pressure diagnosed by a doctor~* high blood cholesterol diagnosed by a doctor~* diabetes or high blood sugar diagnosed by a doctor~* a first degree relative (for example, mother, father, brother, sister) who had a heart condition before the age of 50~* smoke cigarettes now.~* History of allergy to aminoglycosides (e.g. gentamycin)~* History of severe allergy to eggs or egg products e.g., rash or breathing difficulties

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- ADMVA (Type: ACTIVE_COMPARATOR): ADMVA dosage escalation
- Placebo (Type: PLACEBO_COMPARATOR): Placebo is 10mM TRIS HCl, 140mM NaCl, ph 7.7

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete